PUFA vs monounsaturated fatty acid (MUFA): Relapse
It is very uncertain whether polyunsaturated fatty acid (PUFA) changes relapse(assessed as number of participants experiencing relapse) compared with monounsaturated fatty acid (MUFA) (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Polyunsaturated fatty acid (PUFA) vs monounsaturated fatty acid (MUFA) Relapse(assessed as number of participants experiencing relapse) · adults with multiple sclerosis, defined by established criteria It is very uncertain whether polyunsaturated fatty acid (PUFA) changes relapse(assessed as number of participants experiencing relapse) compared with monounsaturated fatty acid (MUFA) (very low certainty). Dietary interventions for multiple sclerosis‐related outcomes (2020) · Cochrane Headline outcomes only | RR 1.02 [0.88, 1.2] | 3 studies · 217 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.